No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects

PURPOSE: Combination therapy with insulin-independent sodium-glucose cotransporter 2 inhibitors and thiazolidinedione drugs, such as lobeglitazone, has been reported to elicit potential additive efficacy in glycemic control in type 2 diabetes mellitus. This study was conducted to evaluate the pharma...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drug Des Devel Ther
Hlavní autoři: Kim, Yu Kyong, Hwang, Jun Gi, Park, Min Kyu
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089085/
https://ncbi.nlm.nih.gov/pubmed/33953542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S302215
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky